SpringWorks Therapeutics Management
Management criteria checks 2/4
SpringWorks Therapeutics' CEO is Saqib Islam, appointed in Jul 2018, has a tenure of 6.58 years. total yearly compensation is $18.35M, comprised of 4% salary and 96% bonuses, including company stock and options. directly owns 0.93% of the company’s shares, worth $27.07M. The average tenure of the management team and the board of directors is 4.7 years and 5.5 years respectively.
Key information
Saqib Islam
Chief executive officer
US$18.4m
Total compensation
| CEO salary percentage | 4.0% |
| CEO tenure | 6.6yrs |
| CEO ownership | 0.9% |
| Management average tenure | 4.7yrs |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate
Jan 13SpringWorks: With Catalyst On The Horizon And Growing Sales, 2025 Looks Great
Dec 31Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks
Dec 15Here's What Analysts Are Forecasting For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Results
Nov 15
SpringWorks Therapeutics Merits A Speculative Buy
Nov 04SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy
Aug 07Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues
May 11We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
May 03SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear
Apr 25SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners
Apr 19We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Sep 20We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate
Jun 07We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Feb 22Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
Nov 09SpringWorks drops 21% as Allogene drops lead asset in combination study
Aug 10SpringWorks Therapeutics GAAP EPS of -$1.41 misses by $0.15
Aug 04Sizing Up SpringWorks Therapeutics
Jul 20Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?
Jun 06SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases
May 02Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth
Dec 30SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline
Dec 14SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Strong Position To Grow Its Business
Sep 15CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$275m |
| Jun 30 2024 | n/a | n/a | -US$301m |
| Mar 31 2024 | n/a | n/a | -US$339m |
| Dec 31 2023 | US$18m | US$725k | -US$325m |
| Sep 30 2023 | n/a | n/a | -US$305m |
| Jun 30 2023 | n/a | n/a | -US$298m |
| Mar 31 2023 | n/a | n/a | -US$289m |
| Dec 31 2022 | US$15m | US$680k | -US$277m |
| Sep 30 2022 | n/a | n/a | -US$259m |
| Jun 30 2022 | n/a | n/a | -US$228m |
| Mar 31 2022 | n/a | n/a | -US$206m |
| Dec 31 2021 | US$18m | US$590k | -US$174m |
| Sep 30 2021 | n/a | n/a | -US$107m |
| Jun 30 2021 | n/a | n/a | -US$87m |
| Mar 31 2021 | n/a | n/a | -US$60m |
| Dec 31 2020 | US$8m | US$541k | -US$46m |
| Sep 30 2020 | n/a | n/a | -US$73m |
| Jun 30 2020 | n/a | n/a | -US$68m |
| Mar 31 2020 | n/a | n/a | -US$62m |
| Dec 31 2019 | US$3m | US$480k | -US$51m |
| Sep 30 2019 | n/a | n/a | -US$41m |
| Jun 30 2019 | n/a | n/a | -US$29m |
| Mar 31 2019 | n/a | n/a | -US$18m |
| Dec 31 2018 | US$2m | US$407k | -US$18m |
Compensation vs Market: Saqib's total compensation ($USD18.35M) is above average for companies of similar size in the US market ($USD6.62M).
Compensation vs Earnings: Saqib's compensation has increased whilst the company is unprofitable.
CEO
Saqib Islam (54 yo)
6.6yrs
Tenure
US$18,351,489
Compensation
Mr. Saqib Islam, J.D. has been Chief Executive Officer and Director at SpringWorks Therapeutics, Inc. since August 2018. He serves as an Independent Director of Passage Bio, Inc. since March 2019. Mr. Isla...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 6.6yrs | US$18.35m | 0.93% $ 27.1m | |
| Chief Financial Officer | 5.5yrs | US$3.74m | 0.038% $ 1.1m | |
| Chief Operating Officer | 4.1yrs | US$6.64m | 0.21% $ 6.0m | |
| Chief Medical Officer | 3.6yrs | US$4.31m | 0.046% $ 1.3m | |
| Chief Accounting Officer | 4.9yrs | no data | 0.015% $ 429.7k | |
| Chief Scientific Officer | 1.4yrs | no data | 0.0087% $ 254.7k | |
| Vice President of Communications & Investor Relations | 7.1yrs | no data | no data | |
| General Counsel & Secretary | 5.1yrs | US$2.83m | 0.030% $ 877.2k | |
| Chief People Officer | 4.5yrs | US$2.52m | 0.021% $ 627.7k | |
| Chief Commercial Officer | 3.9yrs | US$4.94m | 0.027% $ 798.3k |
4.7yrs
Average Tenure
56yo
Average Age
Experienced Management: SWTX's management team is considered experienced (4.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 6.6yrs | US$18.35m | 0.93% $ 27.1m | |
| Independent Director | 5.5yrs | US$520.14k | 0.014% $ 415.4k | |
| Independent Chairman of the Board | 9.1yrs | US$545.14k | 0.41% $ 11.9m | |
| Director | less than a year | no data | no data | |
| Independent Director | 7.5yrs | US$508.45k | 0.014% $ 415.4k | |
| Independent Director | 2.6yrs | US$507.64k | 0.011% $ 314.3k | |
| Independent Director | 4.8yrs | US$520.14k | no data |
5.5yrs
Average Tenure
66yo
Average Age
Experienced Board: SWTX's board of directors are considered experienced (5.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 23:15 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SpringWorks Therapeutics, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Alec Stranahan | BofA Global Research |
| Cory Kasimov | Evercore ISI |